Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Naoko Takebe" Clear advanced filters

  • Modern genomics technologies enable the identification of genetic alterations, even those present at a low frequency, and can contribute to unveiling the mechanistic rationale behind the unexpected clinical response of 'exceptional responders'. This approach will drive the identification of molecular biomarkers that can be integrated into clinical trials and predict response to a specific therapy.

    • Naoko Takebe
    • Lisa McShane
    • Barbara Conley
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 12, P: 132-134

  • In Japan, it is quite rare for an investigator to submit an investigational new drug application to initiate a clinical trial and obtain approval of a drug on the basis of clinical trial results. This means that development of new therapies is currently driven almost entirely by pharmaceutical companies as opposed to independent investigators. Here, we provide our perspective on the reasons for this situation and advocate investigator-initiated cancer drug development as a means of increasing access to better therapies for Japanese cancer patients.

    • Chiyo K. Imamura
    • Naoko Takebe
    • Naoto T. Ueno
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 7, P: 127-128

  • Selectively targeting cancer stem cells with novel therapeutics is gaining importance because disease recurrence after treatment-induced remissions is a major cause of morbidity and mortality. This Review discusses the pathways that are active during development, specifically the Wnt, Notch, and Hedgehog pathways, and the clinical development of therapeutic agents that target these pathways.

    • Naoko Takebe
    • Pamela J. Harris
    • S. Percy Ivy
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 8, P: 97-106

  • Cancer stem cell (CSC) populations are increasingly recognized in most malignancies and are hypothesized to contribute to cancer proliferation, relapse, and metastasis. Thus, the highly conserved stem-cell signal transduction pathways involved in development and tissue homeostasis that are frequently active in CSCs represent prime targets for targeted therapies against this characteristically treatment-resistant and highly tumorigenic cell population. This Review provides a update on the clinical development of therapies targeting Wnt, Notch, and Hedgehog, three prominent stem-cell signalling pathways that are upregulated in CSCs.

    • Naoko Takebe
    • Lucio Miele
    • S. Percy Ivy
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 12, P: 445-464